This review provides comprehensive information on the association of SCAP/SREBP and de novo lipogenesis, its relation to hepatic steatosis, molecular features of SCAP/SREBP activity, and current studies and developments in targeting the SCAP/SREBP in the pharmacotherapy of hepatic diseases. Here, SCAP is linked to fatty liver disease.